Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant

Pediatric Blood and Cancer

Volumn 58, Issue 3, 2012, Pages 459-461

  Bonney, Denise K ^a   Htwe, Ei E ^a   Turner, Andrew ^a   Kelsey, Anna ^a   Shabani, Abdu ^a   Hughes, Stephen ^a   Hughes, Imelda ^a   Wynn, Robert F ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

CNS; EBV; Lymphoproliferative disease; Rituximab

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; HYDROCORTISONE; MELPHALAN; METHOTREXATE; RITUXIMAB; VINCRISTINE;

ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MALE; POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; SYMPTOM; VIRUS INFECTION; X CHROMOSOME LINKED DISORDER;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, SPINAL; LEUKEMIA, B-CELL; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; LYMPHOPROLIFERATIVE DISORDERS; MAGNETIC RESONANCE IMAGING; MALE; VIRUS ACTIVATION;

EID: 84855791932     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23134     Document Type: Article

References (9)

1. WHO classification of tumours of haematopoietic and lymphoid tissue, 4th edition. Geneva, Switzerland: WHO Press; 2008.
2. Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: Significance of central nervous system involvement. Transplant Proc 2005; 37: 954-955.
3. Haque T, Wilkie G, Jones M, et al. Allogeneic cytotoxic T cell therapy for EBV positive post-transplantation lymphoproliferative disease: Result of multicentre clinical trial. Blood 2007; 110: 1123-1131.
4. Wynn RF, Arkwright PD, Haque T, et al. Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol 2005; 6: 344-346.
5. Davis JE, Moss DJ. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 2004; 63: 285-292.
6. Dietlein M, Pels H, Schulz H, et al. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol 2005; 74: 348-352.
7. Dietrich P-Y, Scamuffa N, Saas P, et al. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J Immunol 2000; 165: 3128-3135.
8. Glind G, Graaf S, Klein C, et al. Intrathecal Rituximab treatment for paediatric post-transplant lymphoproliferative disorder of the CNS. Pediatr Blood Cancer 2008; 50: 886-888.
9. Stephan JL, Deist F, Le Blanche S, et al. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody. Transplantation 1992; 54: 246-249.